On Aug. 20, 2020, Sorrento Therapeutics and SmartPharm Therapeutics announced  the signing of a merger agreement under which Sorrento acquired SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential for application in enhancing antibody-centric therapeutics.